Saturday 17 October 2026
Export NXTC’s income statement to Excel — free account
NextCure, Inc.
NXTC Healthcare Biotechnology
In the quarter to June 2026, EPS grew 75.2% and free cash flow grew 57.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.24
0.64
−9.30%
Follow NXTC
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 | — | — | — | — | — |
Altman Z-Score |
— | — | 15.73 | 14.11 | — | — | — | — | — |
P/S ratio |
— | — | 139.24 | 10.96 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | 14.27 | 27.65 | — | — | — | — | — |
P/FCF ratio |
— | — | 0.00 | 0.00 | — | — | — | — | — |
P/Operating CF |
— | — | (88.45) | (47.78) | — | — | — | — | — |
P/B ratio |
— | — | 2.75 | 1.02 | — | — | — | — | — |
Price to Tangible BV |
— | — | 2.75 | 1.02 | — | — | — | — | — |
EV/Sales |
— | — | 87.04 | 0.67 | — | — | — | — | — |
EV/EBITDA |
— | — | 0.00 | 0.00 | — | — | — | — | — |
EV/Operating CF |
— | — | (15.51) | (0.41) | — | — | — | — | — |
EV/FCF |
— | — | (14.17) | (0.35) | — | — | — | — | — |
Quick Ratio |
2.97 | 13.17 | 22.36 | 27.62 | 33.23 | 17.52 | 15.73 | 7.17 | 3.96 |
Current Ratio |
3.02 | 13.19 | 22.60 | 27.89 | 34.48 | 17.97 | 16.38 | 7.50 | 4.14 |
Net Debt/EBITDA |
0.56 | 6.28 | 9.52 | 7.45 | 3.45 | 2.33 | 1.67 | 1.18 | 0.75 |
Debt/Assets |
4.42% | 0.31% | 1.40% | 1.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.06 | 0.00 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.03 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.81 | (0.35) | 1.06 | 1.23 | 0.83 | 0.72 | 0.84 | 0.73 | 0.89 |
Capex/Depreciation |
(14.87) | (1.83) | (1.25) | (2.09) | (0.33) | (0.30) | (0.28) | (0.29) | 0.00 |
| 43.36% | 63.90% | (24.58%) | (11.90%) | (26.33%) | (37.28%) | (44.49%) | (61.87%) | (111.23%) | |
| (18.52%) | (27.29%) | (13.39%) | (11.04%) | (25.28%) | (35.04%) | (40.18%) | (53.28%) | (85.23%) | |
ROIC |
(135.71%) | 0.00% | 0.00% | (214.00%) | (320.61%) | (622.69%) | (690.51%) | 0.00% | 0.00% |
Return on Tangible Assets |
(94.80%) | (16.65%) | (10.01%) | (12.47%) | (29.50%) | (44.82%) | (54.60%) | (82.22%) | (153.19%) |
Average Days of Receivables |
— | — | 0.00 | 0.00 | — | 0.00 | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 539.09% | 208.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 151.46% | 76.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 29.71% | 35.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | 0.35 | 0.92 | — | — | — | — | — |
Graham Number |
— | — | 0.00 | 0.00 | — | — | — | — | — |
Earnings Yield |
— | — | (10.27%) | (12.21%) | — | — | — | — | — |
Free Cash Flow Yield |
— | — | (4.41%) | (17.36%) | — | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 4.85 | 9.76 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(109.77) | 70.04 | (27.25) | (19.60) | (24.90) | (23.32) | (22.85) | (17.51) | (17.45) |
Capex per Share |
(75.89) | (26.84) | (2.58) | (3.11) | (1.03) | (0.92) | (0.35) | (0.20) | 0.00 |
Free Cash Flow per Share |
(185.67) | 43.20 | (29.83) | (22.71) | (25.93) | (24.23) | (23.20) | (17.71) | (17.45) |
Cash per Share |
81.46 | 1,188.72 | 257.24 | 124.34 | 95.46 | 69.19 | 46.70 | 29.45 | 14.71 |
Shareholders Equity per Share |
136.74 | 1,010.33 | 245.90 | 128.07 | 101.45 | 72.49 | 49.34 | 28.09 | 12.29 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
136.74 | 1,010.33 | 245.90 | 128.07 | 101.45 | 72.49 | 49.34 | 28.09 | 12.29 |
Free Cash Flow |
(21.17) | 4.93 | (38.99) | (52.09) | (59.64) | (56.00) | (53.79) | (41.28) | (49.61) |
Working Capital |
6.30 | 125.49 | 324.95 | 277.65 | 221.21 | 154.86 | 105.84 | 62.23 | 33.18 |
Capital Expenditures |
(8.65) | (3.06) | (3.37) | (7.13) | (2.36) | (2.12) | (0.82) | (0.47) | — |
Net Current Asset Value |
5.54 | 103.44 | 305.31 | 275.06 | 218.82 | 147.35 | 99.11 | 56.42 | 28.51 |
EV/EBIT |
— | — | 0.00 | 0.00 | — | — | — | — | — |
Capex to Sales |
0.00 | 0.00 | 0.53 | 0.32 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
— | — | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.06 | 0.15 | 0.22 | 0.22 | 0.51 | 0.60 | 0.32 | 0.30 | 0.52 |
Cash ROIC |
(82.25%) | 1.96% | (5.88%) | (8.94%) | (13.17%) | (17.10%) | (24.15%) | (30.78%) | (64.63%) |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | 0.00 | 0.00 | — | — | — |
Average Payables |
1.81 | 1.81 | 2.17 | 2.88 | 2.92 | 3.11 | 3.30 | 3.84 | 3.68 |
Average Assets |
83.55 | 83.55 | 251.90 | 331.41 | 274.52 | 213.27 | 156.10 | 104.45 | 65.52 |
Average Common Equity |
(35.68) | (35.68) | 137.27 | 307.60 | 263.55 | 200.46 | 140.98 | 89.95 | 50.21 |
Columns are period end dates